Neuraxis Inc (NRXS)

$2.98

+0.12

(+4.2%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.97
    $2.99
    $2.98
    downward going graph

    0.34%

    Downside

    Day's Volatility :0.67%

    Upside

    0.33%

    downward going graph
  • $1.80
    $6.93
    $2.98
    downward going graph

    39.6%

    Downside

    52 Weeks Volatility :74.03%

    Upside

    57.0%

    downward going graph

Returns

PeriodNeuraxis IncIndex (Russel 2000)
3 Months
-6.14%
0.0%
6 Months
25.21%
0.0%
1 Year
-50.33%
0.0%
3 Years
-50.33%
-19.4%

Highlights

Market Capitalization
16.4M
Book Value
- $0.48
Earnings Per Share (EPS)
-2.21
Wall Street Target Price
7.5
Profit Margin
0.0%
Operating Margin TTM
-283.33%
Return On Assets TTM
-376.39%
Return On Equity TTM
0.0%
Revenue TTM
2.3M
Revenue Per Share TTM
0.52
Quarterly Revenue Growth YOY
-19.7%
Gross Profit TTM
0.0
EBITDA
-7.6M
Diluted Eps TTM
-2.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Neuraxis Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 151.68%

Current $2.98
Target $7.50

Company Financials

FY20Y/Y Change
Revenue
1.9M
-
Net Income
-4.1M
-
Net Profit Margin
-209.83%
-
FY21Y/Y Change
Revenue
2.7M
↑ 40.98%
Net Income
-3.1M
↓ 24.12%
Net Profit Margin
-112.93%
↑ 96.9%
FY22Y/Y Change
Revenue
2.7M
↓ 1.34%
Net Income
-4.8M
↑ 55.54%
Net Profit Margin
-178.05%
↓ 65.12%
FY23Y/Y Change
Revenue
2.5M
↓ 8.37%
Net Income
-14.6M
↑ 205.99%
Net Profit Margin
-594.57%
↓ 416.52%
Q4 FY22Q/Q Change
Revenue
613.1K
↓ 0.92%
Net Income
-13.6K
↓ 99.34%
Net Profit Margin
-2.22%
↑ 333.86%
Q1 FY23Q/Q Change
Revenue
805.1K
↑ 31.32%
Net Income
-2.2M
↑ 15848.12%
Net Profit Margin
-269.95%
↓ 267.73%
Q2 FY23Q/Q Change
Revenue
646.0K
↓ 19.76%
Net Income
-2.2M
↑ 2.86%
Net Profit Margin
-346.06%
↓ 76.11%
Q3 FY23Q/Q Change
Revenue
477.5K
↓ 26.09%
Net Income
-4.9M
↑ 119.37%
Net Profit Margin
-1.0K%
↓ 681.12%
Q4 FY23Q/Q Change
Revenue
531.5K
↑ 11.31%
Net Income
-5.3M
↑ 8.34%
Net Profit Margin
-999.76%
↑ 27.42%
Q1 FY24Q/Q Change
Revenue
646.6K
↑ 21.67%
Net Income
-2.1M
↓ 60.09%
Net Profit Margin
-327.95%
↑ 671.81%
FY20Y/Y Change
Total Assets
2.8M
-
Total Liabilities
1.1M
-
FY21Y/Y Change
Total Assets
760.5K
↓ 72.74%
Total Liabilities
1.6M
↑ 38.43%
FY22Y/Y Change
Total Assets
1.5M
↑ 94.7%
Total Liabilities
7.1M
↑ 344.74%
FY23Y/Y Change
Total Assets
509.5K
↓ 65.59%
Total Liabilities
1.9M
↓ 72.89%
Q4 FY22Q/Q Change
Total Assets
1.5M
↑ 11.17%
Total Liabilities
7.1M
↑ 2.33%
Q1 FY23Q/Q Change
Total Assets
1.6M
↑ 6.6%
Total Liabilities
9.3M
↑ 32.2%
Q2 FY23Q/Q Change
Total Assets
1.5M
↓ 2.45%
Total Liabilities
11.5M
↑ 23.56%
Q3 FY23Q/Q Change
Total Assets
1.2M
↓ 19.73%
Total Liabilities
2.3M
↓ 80.06%
Q4 FY23Q/Q Change
Total Assets
509.5K
↓ 58.78%
Total Liabilities
1.9M
↓ 16.73%
Q1 FY24Q/Q Change
Total Assets
945.7K
↑ 85.62%
Total Liabilities
4.1M
↑ 115.93%
FY20Y/Y Change
Operating Cash Flow
-4.1M
-
Investing Cash Flow
-27.7K
-
Financing Cash Flow
6.1M
-
FY21Y/Y Change
Operating Cash Flow
-2.2M
↓ 46.02%
Investing Cash Flow
-1.4K
↓ 94.99%
Financing Cash Flow
661.1K
↓ 89.08%
Q4 FY22Q/Q Change
Operating Cash Flow
-214.3K
↓ 76.5%
Investing Cash Flow
-7.6K
-
Financing Cash Flow
510.0K
↓ 36.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-622.9K
↑ 190.65%
Investing Cash Flow
-7.6K
↑ 0.0%
Financing Cash Flow
422.3K
↓ 17.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-625.2K
↑ 0.37%
Investing Cash Flow
-5.5K
↓ 28.25%
Financing Cash Flow
636.7K
↑ 50.77%

Technicals Summary

Sell

Neutral

Buy

Neuraxis Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neuraxis Inc
Neuraxis Inc
10.37%
25.21%
-50.33%
-50.33%
-50.33%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neuraxis Inc
Neuraxis Inc
NA
NA
NA
0.0
0.0
-3.76
NA
-0.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neuraxis Inc
Neuraxis Inc
Buy
$16.4M
-50.33%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Neuraxis Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 477.46K → 646.63K (in $), with an average increase of 14.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -5.31M → -2.12M (in $), with an average increase of 150.6% per quarter

Company Information

Organization
Neuraxis Inc
Employees
19
CEO
Mr. Brian Carrico
Industry
Miscellaneous

FAQs